Pumitamig

Pumitamig is a bispecific antibody that targets both PD-L1 and VEGF-A. Pumitamig can be used for the study of solid tumors[1].

Product Specifications

Product Name Alternative

PM-8002; BNT-327

UNSPSC

12352203

Target

PD-1/PD-L1; VEGFR

Related Pathways

Immunology/Inflammation; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Purity

99.6

Smiles

[Pumitamig]

Molecular Weight

(172.48 kDa)

References & Citations

[1]Lingying Wu, et al. Efficacy and safety of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with solid tumors: Clinical data from advanced cervical cancer and platinum-resistant recurrent ovarian cancer cohorts. Journal of Clinical Oncology. Volume 42, Number 16_suppl.